From the Stein Eye Institute and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
From the Stein Eye Institute and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
J Cataract Refract Surg. 2016 Jun;42(6):870-8. doi: 10.1016/j.jcrs.2016.03.035.
To evaluate the safety and efficacy of Morcher 50F iris diaphragm implantation to manage moderate to large defects of the human iris.
Stein Eye Institute, UCLA, Los Angeles, California, USA.
Prospective nonrandomized interventional case series.
The demographic, preoperative, and postoperative data of patients who had implantation of modified capsular tension rings and followed to 1 year were reviewed. Safety measures included loss of corrected distance visual acuity (CDVA), surgical complications, adverse events, and secondary surgical interventions. Efficacy measures included CDVA with glare, daytime and nighttime glare symptom scores, and subjective cosmesis scores.
The study comprised 12 patients. The median CDVA was 20/70 before surgery and 20/20 after surgery. There were no lost lines of CDVA and no intraoperative complications. The most common postoperative complication was posterior capsule opacification. Two adverse events were unrelated to the device. Four patients had secondary surgical interventions, the most common of which was laser capsulotomy. The median CDVA with glare improved from less than 20/400 before surgery to 20/50 after surgery. One patient worsened. The median subjective daytime glare symptom score improved from 9 to 3 on a 10-point scale (P = .001). The median nighttime subjective glare symptom score improved from 8 to 2 (P = .001). The subjective cosmetic appearance of the eye stayed the same or improved for all patients (P = .031).
Iris diaphragm implantation was relatively safe and effective for reducing light and glare sensitivity in eyes with iris defects when combined with cataract extraction and intraocular lens implantation.
None of the authors has a financial or proprietary interest in any material or method mentioned.
评估 Morcher 50F 虹膜膈植入术治疗人虹膜大至中等大小缺损的安全性和有效性。
美国加利福尼亚州洛杉矶加州大学洛杉矶分校 Stein 眼科研究所。
前瞻性非随机干预性病例系列研究。
回顾了植入改良囊张力环并随访 1 年的患者的人口统计学、术前和术后数据。安全性措施包括矫正视力(CDVA)丧失、手术并发症、不良事件和二次手术干预。有效性措施包括眩光时的 CDVA、白天和夜间眩光症状评分以及主观美容评分。
该研究共纳入 12 名患者。术前 CDVA 中位数为 20/70,术后为 20/20。没有 CDVA 丢失线,也没有术中并发症。最常见的术后并发症是后囊混浊。有 2 例不良事件与器械无关。4 例患者进行了二次手术干预,最常见的是激光后囊切开术。眩光时的 CDVA 中位数从术前的低于 20/400 改善至术后的 20/50。1 例患者恶化。10 分制的日间眩光主观症状评分中位数从 9 分改善至 3 分(P=0.001)。夜间主观眩光症状评分中位数从 8 分改善至 2 分(P=0.001)。所有患者的眼部美容外观保持不变或改善(P=0.031)。
当与白内障摘除和人工晶状体植入联合应用时,虹膜膈植入术对于减轻虹膜缺损眼的光和眩光敏感性相对安全且有效。
作者均无任何材料或方法的经济或专有利益。